Overview

Herombopag Treated T-DM1 Induced Platelet Reduction

Status:
RECRUITING
Trial end date:
2027-09-26
Target enrollment:
Participant gender:
Summary
This is a single-arm study planned to enroll 56 breast cancer patients who experienced grade 2 or higher thrombocytopenia following prior chemotherapy and achieved normalization (platelet count 100 109/L and 200 109/L) through intervention.
Phase:
PHASE2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University